Tesamorelin
 | |
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Subkutano |
| Identifikatori | |
| CAS broj | 901758-09-6  |
| ATC kod | H01AC06 (WHO) |
| DrugBank | DB08869 |
| ChEBI | CHEBI:63626 |
Tesamorelin (Egrifta) je sintetička forma hormona faktora rasta koji se koristi u lečenju lipodistrofije vezane za HIV. Tesamorelin je razvilo preduzeće Theratechnologies, Inc. of Canada.[1][2][3][4][5][6][7][8][9]
Reference
[уреди | уреди извор]- ^ Spooner LM, Olin JL: Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. Spooner, L. M.; Olin, J. L. (фебруар 2012). „Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy”. Annals of Pharmacotherapy. 46 (2): 240—7. PMID 22298602. doi:10.1345/aph.1Q629... Epub 2012 Jan 31.
- ^ McLarnon A: Neuroendocrinology: Tesamorelin can improve cognitive function. Nat Rev Endocrinol. McLarnon, Andy (октобар 2012). „Tesamorelin can improve cognitive function”. Nature Reviews Endocrinology. 8 (10): 568. PMID 22926095. doi:10.1038/nrendo.2012.151... Epub 2012 Aug 28.
- ^ Bedimo R: Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). Bedimo, Roger (2011). „Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy”. HIV/AIDS - Research and Palliative Care. 3: 69—79. PMC 3218714
. PMID 22096409. doi:10.2147/HIV.S14561 ... Epub 2011 Jul 10.
- ^ Dhillon S: Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs. Dhillon, Sohita (децембар 2011). „Spotlight on Tesamorelin in HIV-Associated Lipodystrophy†”. Biodrugs. 25 (6): 405—8. PMID 22050344. doi:10.2165/11208290-000000000-00000...
- ^ Garg A: Acquired and inherited lipodystrophies. N Engl J Med. Garg, A. (март 2004). „Acquired and inherited lipodystrophies”. The New England Journal of Medicine. 350 (12): 1220—34. PMID 15028826. doi:10.1056/NEJMra025261.
- ^ Patel A, Gandhi H, Upaganlawar A: Tesamorelin: A hope for ART-induced lipodystrophy. J Pharm Bioallied Sci. Gandhi, Hardik; Patel, Akash; Upaganlawar, Aman (април 2011). „Tesamorelin: A hope for ART-induced lipodystrophy”. Journal of Pharmacy and Bioallied Sciences. 3 (2): 319—20. PMC 3103937 . PMID 21687371. doi:10.4103/0975-7406.80763 ...
- ^ Campbell RM, Lee Y, Rivier J, Heimer EP, Felix AM, Mowles TF: GRF analogs and fragments: correlation between receptor binding, activity and structure. Peptides. ;Campbell, R. M.; Lee, Y.; Rivier, J.; Heimer, E. P.; Felix, A. M.; Mowles, T. F. (1991 May-Jun). „GRF analogs and fragments: Correlation between receptor binding, activity and structure”. Peptides. 12 (3): 569—74. PMID 1656403. doi:10.1016/0196-9781(91)90103-v. Проверите вредност парамет(а)ра за датум:
|date=(помоћ) - ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]- Tesamorelin Архивирано на веб-сајту Wayback Machine (24. август 2014)
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
